Indian Pharmas See Big Advantage In Moving Acquisitions To India
This article was originally published in PharmAsia News
Executive Summary
Indian drug makers that made U.S. and European acquisitions have discovered they can save as much as 40 percent in manufacturing costs by moving production to India. Piramal Healthcare became an example of that success when it moved the inhalation anesthetics acquired from Rhodia of the United Kingdom to its manufacturing facilities in India. The success has led Piramal to consider moving the products of its U.S. acquisition, Minrad International, to India. Dr. Reddy's is considering a similar production shift. (Click here for more
You may also be interested in...
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.
EU Stakeholders Devise Six-Point Plan To Improve Cross-Border Clinical Trials
Sponsors need guidance on ethics requirements and clarity around national regulations to conduct cross-border clinical trials in the EU, a multi-stakeholder forum says.